R arthritis (RA) is a potentially very disdirected against IgG-AGE. Subsequent analysis of diabetics and of patients with other rheumatic diseases abling disease with both articular and systemic manifestations. Our understanding of its pathogenesis showed that the antibody response to glycated IgG was primarily associated with RF-positive RA. The remains partial and treatment is generally not curative. Long-term outcome predictors, such as the presence IgM anti-IgG-AGE antibodies and RF appear to be two separate and probably distinct antibody populaof rheumatoid factor (RF ) [1] [2] [3] [4] [5] and the QKRAA shared epitope on the HLA-DRb chain [6] [7] [8] , help tions. We discuss the potential role of IgG-AGE and anti-IgG-AGE antibodies in the pathogenesis of RA. clinicians decide how aggressive treatment should be. However, the picture they provide remains incomplete PATIENTS AND METHODS and the search continues for better prognostic tools.
A previously unsuspected factor which seems to Patients and controls correlate with clinical disease activity in RA is the level IgG-AGE and IgM anti-IgG-AGE antibodies were of certain circulating advanced glycation end products originally identified in three patients with RA (see (AGE ) [9] . Primarily studied in the diabetic populabelow for test methods). A retrospective chart review tion, where they appear to be implicated in tissue was undertaken for each patient. damage, their occurrence and clinical significance
In a retrospective study, sera were drawn from in RA had not been previously assessed. AGE result randomly selected patients with various rheumatic from non-enzymatic glycation of proteins [10] .
diseases from clinics at the Montreal General Hospital Haemoglobin (glycated form haemoglobin A1c), albu-(Drs C. Watts, J. Esdaile and P. R. Fortin), Notremin and collagen have all been identified as targets of Dame Hospital (J. P. Pelletier) and the Toronto AGE modification [10] . Increasingly recognized is the Western Hospital (Dr R. Inman). Diseases included glycation of immunoglobulins ( [11] [12] [13] [14] [15] and Newkirk, RA, systemic lupus erythematosus (SLE ), Sjö gren's revised manuscript submitted ], which has been shown syndrome (SS ), spondyloarthritis, adult Still's disease to have functional implications such as decreased proand osteoarthritis (OA). Diabetics, 16 Type 1 and 14 tein A binding and complement fixation [13] , as well Type 2, selected for elevated haemoglobin A1c (Dr R. as decreased antigen binding ( [14, 15] and Newkirk, Gardiner, Montreal General Hospital ) and 20 healthy revised manuscript submitted ). controls, with a mean age of 32.6 ± 10.0 yr (14 We recently identified three RA patients with severe female:6 male) were also selected. Information on a systemic manifestations in whom we found both IgG number of different clinical parameters, blood glucose modified with advanced glycation end products (IgGlevels and haemoglobin A1c ( HbA1c; values >6.1 AGE ), and elevated titres of IgM and IgA antibodies were considered elevated ), were obtained where available from the charts. IgG-AGE with those of five RA patients, eight dia-AGE modified after being sterilized by passing through betics and five healthy individuals without IgM-antia 20 mm filter. The IgG was incubated in vitro with IgG-AGE. Following isolation of immune complexes 1.5  glucose for 3 months at 37°C in order to modify (as described above), 15 mg of total protein were it fully with the AGE. The amount of AGE modificaresolved in 10% SDS-PAGE under reducing conditions tion on purified IgG was followed by measuring the and transferred as above for immunoblotting. The optical density at 335 mm where the browning or relative amounts of CML as detected by the monopentosidine cross-links on the purified protein can be clonal antibody 6D12 on the heavy and light chains of detected [17] .
the IgG were determined by laser densitometry, and then corrected for the amount of total IgG (blots were Nitroblue tetrazolium (NBT) colorimetric method stripped and reprobed with anti-human IgG). For this assay, which has been modified from previously published methods [18, 19] , serum was fractionMeasurement of antibodies to immunoglobulin-AGE ated into an antibody/immune complex-rich fraction IgM anti-IgG-AGE antibodies were detected in and other proteins, using a polyethylene glycol precipserum or plasma, using an ELISA assay that we have itation (PEG) method that we have developed. One established. Fully AGE-modified IgG (all four subhundred microlitres of serum were incubated with 2.5% classes) (2 mg/ml ) to which there is minimal RF binding PEG 8000 for 30 min at 4°C. The samples were centriwas used to coat the wells of an EIA plate (ICN ). fuged at 15 000 g for 5 min. The supernatant was After washing the plates, the sera or plasma, diluted collected ('other' proteins) and the pellet (IgG-con-1:1000 or greater, in duplicate, were incubated in the taining immune complexes) was resuspended in 100 ml AGE-modified Ig-coated wells for 2 h at 37°C. After of phosphate-buffered saline (PBS). Fifty microlitres washing the plates in PBS/Tween (0.1%), the bound of the supernatant and resuspended pellet were added antibodies were detected with peroxidase-conjugated to the wells of 96-well microtitre plates, in duplicate. IgG-AGE antibodies bound to AGE modifications on NBT in 0.1  carbonate buffer (pH 10.35)] were added other proteins, ELISA plates were coated with BSA to each well, then incubated at 37°C for 2 h. The plate with and without AGE modifications (2 mg/ml ) and was read in an ELISA plate reader at OD 550. The the bound antibodies ( IgG, IgM ) were detected using amount of AGE-modified proteins in the fractions was appropriate HRP-conjugated second antibodies. calculated using IgG-AGE (for the pellet) and BSAValues were considered positive when they were above AGE (for the supernatant) standard curves.
2 .. of the mean of the reactivity of 20 normal individuals. To follow the reactivity over time, and Immunoblots for AGE-IgG detection keep consistent results, a serum from one normal Validation of the NBT assay, and further structural individual (approximately the mean reactivity) was characterization of the AGE epitope, was done by tested each time the assay was performed. immunoblotting. In brief, 1 ml of the immune complex fraction (as above) was resolved on 10% SDS-polyIgM anti-IgG-AGE binding specificity studies acrylamide gels, under reducing conditions, as previ-
The binding specificities of IgM anti-IgG-AGE antiously described [20] . After transfer to nylon bodies were determined and compared to that of RFs. membranes [21] , the membranes were blocked with For this polyclonal RFs obtained from 53 RF-positive 0.1% Tween 20 in PBS for 1 h at room temperature.
RA patients were reacted to all four subclasses of IgG The AGE determinant was detected using a 2 h incuba-(included are the 41 patients reported in Table II with tion at 37°C with the monoclonal antibody 6D12 an additional 12) and binding specificities were deter-( Wako), specific for Ne (carboxymethyl ) lysine (CML) mined. Similarly, the binding specificities to fully AGE- [22] , diluted 1:1000 in PBS/Tween. After washing the modified IgG of all four subclasses, to which there was blots, the bound 6D12 was detected after incubating minimal RF reactivity (Newkirk, revised manuscript for 1 h at 37°C with HRP-anti-mouse IgG (1:30 000).
submitted ), were determined in 37 RF-positive RA A chemiluminescent ECL (Amersham) was used, with patients who also had IgM anti-IgG-AGE. visualization on BioMax film ( Kodak). To identify the RESULTS components in the immune complexes, the blot was stripped according to the ECL recommendations, and
The clinical characteristics of three RA patients in whom IgG-AGE and IgM anti-IgG-AGE were initially reprobed with horseradish peroxidase (HRP)-anti-identified are summarized in Table I . All three patients RA, 22/43 (51%) had IgA RFs, whereas 10/43 (23%) had IgA-anti-AGE antibodies. IgA RF was detected had RF-positive destructive erosive disease, with associated vasculitis, and required corticosteroids as part in 1/13 patients with spondyloarthritis. No IgA antiIgG-AGE antibodies were detected in the spondyloof their treatment. Although none of these three individuals carried a diagnosis of diabetes mellitus, their arthritis group. Immunoblots of immune complexes (IC ) isolated available random serum glucose levels were increased or at the high end of normal. Unfortunately, fasting from 1 ml of serum from the three described RA patients, using a monoclonal anti-CML antibody, blood glucose levels were unavailable. All were found to have elevated RF titres. IgG-AGE and IgM antirevealed AGE modification of both heavy and light chains (Fig. 1) . This was not observed in the IC IgG-AGE were detected in these three patients ( Table II ) . The RA patients had levels of IgG-AGE isolated from the two diabetics or the two normal individuals. We have, however, detected CML on the modifications similar to those of the diabetics and greater than the healthy controls. The IgM anti-IgGIgG isolated from other diabetics ( Fig. 2) . Fragments of C3 were detected in the sample, along with the IgG AGE titres were elevated in the RA patients (titres against IgG1 were 1/160 000, 1/20 000 and 1/8000, and the IgM, indicating the presence of the IC in the RA sera ( Fig. 1) . The molecular weight of the heavy respectively, for patients 1, 2 and 3; results in Table II are given in units), whereas IgM anti-IgG-AGE levels chain modified with CML was consistent with that of IgG and not IgM. were not detected in the two representative diabetics or the two normal individuals shown. The IgM antiAs can be seen in Fig. 2 , after correction for the total amount of IgG in the blot, significantly more IgG-AGE titres were much lower than the RF titres in these three index RA patients (data not shown).
CML was detected on the IgG in the IC of RA patients with circulating anti-IgG-AGE than in IC of RA Slight differences amongst the three cases were observed in the IgM anti-IgG-AGE specificity for the patients or normal individuals without anti-IgG-AGE (P < 0.001). All 10 RA patients tested had normal subclasses of IgG: all four subclasses were recognized in cases 2 and 3, whereas case 1 recognized AGEHbA1c values; one patient without anti-IgG-AGE antibodies had an elevated blood glucose value of modified IgG1, IgG2 and IgG4 better than IgG3-AGE. IgA anti-IgG-AGE antibodies were detected in patients 8.2 mmol/l (normal value <6.5). The type 1 diabetics had similar amounts of CML present on the heavy 1 and 2 (data not shown). Two out of the three RA patients were found to have both an IgG and an IgM chain regardless of the presence or absence of the antiIgG-AGE antibodies, although the numbers are small anti-BSA-AGE response ( Table II ) , but their antibodies did not detect BSA that was not AGE modified (data not shown). CML was also detected on the light chain, and showed the same trend (higher in the RA (data not shown). No anti-BSA-AGE antibody response was identified in the two normal individuals patients with circulating anti-IgG-AGE antibodies), although with more variability (data not shown). or the two diabetic patients illustrated.
Fifty-three additional RA patients were tested, retroLinear correlation analyses of the HbA1c levels of the diabetics with albumen-AGE or IgG-AGE measurespectively, for the presence of IgM anti-IgG-AGE ( Table III ) . A total of 20/41 (49%) of the RF-positive ments made by the NBT assay revealed a highly significant correlation (r = 0.78, P = 0.0009) for albupatients had elevated IgM anti-IgG-AGE titres, while none of the 12 RF-negative RA patients (0%) had min-AGE, but no significant correlation was found for the IgG-AGE (r = 0.95, P = 0.75). detectable titres. There were no significant differences in steroid use in the RF-positive vs the RF-negative Binding specificity studies revealed that RF from the RA patients bound preferentially to IgG1, 2 and 4, groups. Additionally, in this study group, there was no correlation between the RF titre (as determined by with little binding to IgG3. Only 1/53 (2%) bound IgG3 better than IgG1, 2 and 4. In contrast, testing of ELISA) and the anti-IgG-AGE response. Anti-IgG-AGE antibodies were detected in 4/12 (33%) of the 37 RA patients with circulating IgM anti-IgG-AGE (all had RF and were included in the above RF RF-positive SLE patients, and in 3/5 of RF-positive patients with SS, and 3/5 RF-positive diabetics. None specificity studies) showed that 16/37 (43%) had preferential antibody binding to IgG3. of the RF-negative diabetics (types 1 or 2), SLE or SS patients had anti-IgG-AGE antibodies. Anti-IgG-AGE DISCUSSION antibodies were undetectable in 20 healthy controls, in the 25 RF-negative diabetics tested, and in patients
The three patients described, in whom the IgM antiIgG-AGE antibody was initially discovered, shared with OA, spondyloarthritis or adult-onset Still's disease. A total of 9/35 (26%) RF-positive RA patients several important characteristics. All had particularly aggressive RF-positive RA with vasculitis. All required tested had detectable IgM anti-BSA-AGE antibodies, while 6/35 (17%) had an IgG anti-BSA-AGE response.
continuous corticosteroid treatment. Identifying a new autoantibody in such a setting immediately raises quesOf the diabetics with IgM anti-IgG-AGE antibodies, two had detectable IgM-anti-BSA-AGE antibodies.
tions as to its diagnostic, prognostic and pathogenic roles. Several points can be made from the presented No information was available on the blood glucose levels of the patient groups, other than the diabetics.
data. Firstly, AGE-modified IgG are found in nonovertly diabetic RA patients. In a subsequent prospectThe IgA RF and anti-AGE response was also determined in some patient groups. For the patients with ive study of 62 patients with RA, only 7% had hyperglycaemia (preliminary data, not shown). to RF is probably associated with the glycoxidation of the target antigen, namely IgG. These authors suggest Secondly, RF-positive individuals, primarily RA patients, can mount an antibody response to IgGthat the increased oxidant stress in uncontrolled RA was responsible for the presence of increased serum AGE. Finally, this antibody response appears to be strongly linked to the production of RF.
and urinary pentosidine; however, they did not identify the proteins modified by this AGE epitope. Similarly, Previous studies by Takahashi et al. [9] have shown that the AGE modification product pentosidine (which a recent study by Rodriquez-Garcia and co-workers [23] reports elevated levels of pentosidine in patients cross-links lysine and arginine) can be detected in elevated amounts in patients with RA. Approximately with RA, in the absence of hyperglycaemia; again the modified protein(s) were not identified. Reactive 50% of the RA patients in their study had elevated pentosidine levels >2 .. of the normal mean. Thus, oxygen radicals have been identified in 90% of RA synovial fluids [24] . In blood, the reactive oxygen this represents a significantly larger subset of patients than those with elevated blood glucose. Interestingly, radicals have been found to correlate with tumour necrosis factor alpha [25] . Such radicals can contribute they found that pentosidine correlated with clinical disease activity [9] . Of note is the association they to the formation of advanced glycation end products [22, 26, 27] . report between RF and urinary pentosidine. Since we have not detected glycated IgM (and by association
In our study, we have identified AGE-modified IgG in RA patients, as illustrated by the detection of CML, IgM RFs) in patients with RA, this link of pentosidine did find a highly significant correlation, however, between HbA1c and albumin-AGE. In the three initial cases, random blood sugars were at the upper limit of normal, or slightly above normal. The true incidence of diabetes in RA is unknown, but intermittent hyperglycaemia is generally felt to be a common occurrence. The clinical significance of IgG-AGE in RA remains to be determined, although, as previously demonstrated, IgG glycation does impair both antigen binding and effector functions, and may render patients prone to infections ([13-15] and Newkirk, manuscript submitted ). Hyperglycaemia in RA probably results from the use of corticosteroids and from the greater secretion of stress hormones, such as cortisol and epinephrine, in response to inflammation. However, this has been disputed [28] . It does appear that patients with RA have peripheral insulin resistance which probably contributes to the hyperglycaemia [29] . Interestingly, moderate dose corticosteroids may actu- ation [10] . The longer half-life of IgG, being~1 month, as opposed to the 9 days for IgM, may explain why IgG-AGE, but not IgM-AGE, was detected in these patients.
The increase in IgG-AGE in patients with RA may also result from a decrease in its clearance. Soluble AGE-modified proteins are cleared by the reticuloendothelial system via specific AGE receptors, such as RAGE [31] . It is possible that IgM anti-IgG-AGE antibodies block IgG-AGE clearance by binding to IgG-AGE and thus preventing recognition via these receptors. The significant elevation in IgG-AGE in RA patients with circulating anti-IgG-AGE compared to those without (Fig. 2) , despite similar glycaemic control in both groups, supports the hypothesis that anti-IgG-AGE antibodies may diminish IgG-AGE clearance. and because they both target IgG, it was important to ensure that these are indeed two separate antibody populations. There are five points that can be made in the AGE modification of lysine. CML was detected on both heavy and light chains. In previous studies of support of this contention. (i) Only half of the RF-positive RA patients were in fact found to have diabetics, the level of glycosylated IgG has been shown to correlate with HbA1c measurements [12] , although circulating IgM anti-IgG-AGE. It is likely, however, that a few of the anti-IgG-AGE-negative individuals we could not confirm this using the NBT assay. We will with time develop such antibodies (as we have more severe disease in which hyperglycaemia is more common, the presence of the anti-AGE antibody, observed, data not shown). (ii) In separate expericombined with greater levels of glycated IgG, may ments, we have shown that monoclonal RFs from favour IC deposition. Elevated serum glucose levels patients with mixed cryoglobulinaemia do not bind to would be particularly deleterious in these patients. fully AGE-modified IgG, implicating specific lysine Our first described patient had systemic amyloidosis, and arginine residues in the Fc as being involved in presumably of the AA type, which is associated with the recognition of RFs (Newkirk, Because the presence of IgM anti-IgG-AGE always One of the structural differences between IgG3 and the appears to be associated with that of RF, it may not other IgG subclasses is its long hinge region, which prove to be helpful in the diagnosis of RA. However, contains four lysine and four arginine residues, all of from preliminary studies, we have found that antiwhich could potentially be AGE modified. Additional
IgG-AGE antibodies correlate with greater disease studies are required to determine whether the hinge activity (Lucey, manuscript submitted). Thus, it may region of IgG3 is a site of AGE modification, and a be directly involved in tissue damage. Our study raises binding site for IgM anti-IgG-AGE. (v) The precise the issue of the potential importance of good glycaemic specificities of the anti-AGE antibodies are as yet control in RA, and of cautious use of chronic corticounknown; however, we suspect that the majority of steroid therapy. the antibodies will be directed at an epitope containing Prospective follow-up of RA patients, with testing CML, as has been seen for polyclonal rabbit antisera for IgM anti-IgG-AGE and close attention to glucose raised to other AGE-modified proteins [32] . Our data levels, will help determine the prognostic value of this showing that there is an increase in the CML-IgG in new autoantibody. Further information about the the IC of patients with anti-IgG-AGE antibodies are interaction of anti-IgG-AGE with specific IgG-AGE consistent with this previous finding. The fact that epitopes is, however, required. In addition, the impact CML is immunogenic (rabbits and mice make antibodof circulating anti-IgG-AGE antibodies on the clearies against it) further strengthens our finding of antiance of IgG-AGE and other AGE-modified proteins AGE antibodies in humans. These points all provide in animal models of arthritis needs assessment. evidence that RF and IgM anti-IgG-AGE represent Localizing IgG-AGE/IgM anti-IgG-AGE immune two different antibody populations.
complex deposits in the endothelium and synovium of The explanation for the association between the two RA patients with the circulating antibody would supantibody populations may lie at the level of the immune port a direct pathogenic role. dysregulation triggering their production. postulates that IgM-anti-IgG-AGE is associated with
